-
Mashup Score: 3November 1, 2023 - Foundation For Women's Cancer - 6 month(s) ago
Your Stories Then and Now: Former FWC Research Awardee Presents Promising Clinical Trial Results on an International Stage Supporting gynecologic cancer research is central to the mission of the Foundation for Women’s Cancer (FWC). Research funding is
Source: foundationforwomenscancer.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Gyn Cancer Research News - July 12, 2023 - 10 month(s) ago
We are happy to once again be sharing the latest Gynecologic Cancer Research News as we cover studies from this year’s #SGOmtg and #ASCO23 A…
Source: gyncsm.blogspot.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @gyncsm: Join/Share: #GynCSM (Gynecologic Cancer Social Media) tweet chat Wed Jul 12th at 8pmET. https://t.co/ulXLaBbm5q https://t.co/z…
-
-
Mashup Score: 1FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer - 11 month(s) ago
The FDA has accepted and granted priority review to a supplemental biologics license application seeking the approval of dostarlimab plus chemotherapy for use in adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.
Source: OncLiveCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @OncLive: .@US_FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer #gyncsm https://t.co/loX9eSD0gy
-
-
Mashup Score: 3Study Finds T-DXd Effectively Treats HER2-Expressing Cancers, Regardless of Tumor Location - The ASCO Post - 11 month(s) ago
By The ASCO Post Staff Posted: 6/5/2023 9:27:00 AM Last Updated: 6/5/2023 1:23:23 PM According to the findings of the international phase II DESTINY-PanTumor02 study presented by Funda Meric-Bernstam, MD, and colleagues at the 2023 ASCO Annual Meeting, fam-trastuzumab deruxtecan-nxki (T-DXd) is an effective…
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ASCOPost: Study Finds T-DXd Effectively Treats HER2-Expressing Cancers, Regardless of Tumor Location https://t.co/jPOHB8Aj06 #oncology…
-
-
Mashup Score: 2
Note: Due to the number of Tweets embedded in this post the page may take some time to load. This year I attended #ASCO23 virtually. Some of…
Source: womenofteal.blogspot.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @womenofteal: First #ASCO23 blog post - Day 1 Cervical Cancer, HIPEC, Antibody Drug Conjugates in Gyn Cancers https://t.co/odiptXDqBb #…
-
-
Mashup Score: 7Drug Shortages - 11 month(s) ago
Ask your lawmakers to take steps to mitigate drug shortages.
Source: asco.quorum.usCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @womenofteal: I asked my lawmakers to take action to mitigate drug shortages. #ASCOAdvocacy https://t.co/XmvAPe7JXR #gyncsm I was treat…
-
-
Mashup Score: 3
Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.Researchers observed favorable surgical outcomes — even among women with stage IV disease — after only two cycles of the poly(ADP-ribose) polymerase (PARP)
Source: www.healio.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @HemOncToday: Neoadjuvant olaparib feasible for women with germline-mutant ovarian cancer. https://t.co/Y5eGcFTlZe #OvarianCancer #SGOM…
-
-
Mashup Score: 3Gala - Ovarcome - 1 year(s) ago
You Are Cordially Invited To: Ovarcome Annual Appreciation Night, 2023 Saturday, May 20, 2023, 6:30 PM – 10:00 PM Benefitting & Honoring: Women Diagnosed with Ovarian Cancer Hotel Royal Sonesta 2222 W Loop S, Houston, TX 77027 Tickets SPONSOR SHARE AUCTION Support the OVARCOME Gala today! Share information. Purchase tickets. Support Ovarian Cancer Awareness. Celebrate […]
Source: OvarcomeCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ovarcome: While you watch the #Oscars2023......save the date for our OVARE: Ovations Night on 5/20! 🎉 https://t.co/I0w0i7AorM https:/…
-
-
Mashup Score: 1
REGISTER HERE FOR EDUCATION DAY 1 It’s time to show our ZEAL FOR TEAL! Join us from where you are WORLDWIDE, on March 22 for a full day of learning, mingling, and OVARCOMING – VIRTUALLY! We look forward to seeing YOU. Let’s show our ZEAL FOR TEAL!
Source: ZoomCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ovarcome: SIGN UP via this direct link for Education Day 1: https://t.co/qCtDfzWKTs FREE event🌎, thanks to all our Sponsors! Top Global…
-
-
Mashup Score: 1Treatment Complexities Continue to Mount in Gynecologic Cancers - 1 year(s) ago
Data concerning the long-term benefit of PARP inhibitors as maintenance therapy for select patients with ovarian cancer in later-line settings have come under fire in 2022 as several agents have failed to demonstrate improvements in OS outcomes.
Source: OncLiveCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @OncLive: Treatment Complexities Continue to Mount in Gynecologic Cancers https://t.co/3H8IGpweB8 @ShannonWestin @MDAndersonNews @uamshe…
-
RT @GreggNelsonERAS: Congrats @ShannonWestin 👏 🥳 @SGO_org @GYNCancer @myESMO https://t.co/p8IhTYnzNu